FDA Revised Strategy Toward Health Claims Requested By Pearson Plaintiffs
This article was originally published in The Tan Sheet
Executive Summary
A revision of FDA's strategy for dealing with the four health claims the agency was ordered to reconsider under the Pearson v. Shalala decision is requested by plaintiffs' counsel Jonathan Emord (Washington, D.C.-based Emord & Associates) in a Sept. 23 letter to the agency. The letter asks FDA to notify the plaintiffs of such changes by Oct. 15.